Structure-based design of guanosine analogue inhibitors targeting GTP cyclohydrolase IB towards a new class of antibiotics.

Bioorg Med Chem Lett

Department of Chemistry and Biochemistry and the Viral Information Institute, San Diego State University, San Diego, CA 92182, USA. Electronic address:

Published: January 2020

GTP cyclohydrolase (GCYH-I) is an enzyme in the folate biosynthesis pathway that has not been previously exploited as an antibiotic target, although several pathogens including N. gonorrhoeae use a form of the enzyme GCYH-IB that is structurally distinct from the human homologue GCYH-IA. A comparison of the crystal structures of GCYH-IA and -IB with the nM inhibitor 8-oxo-GTP bound shows that the active site of GCYH-IB is larger and differently shaped. Based on this structural information, we designed and synthesized a small set of 8-oxo-G derivatives with ether linkages at O and O expected to displace water molecules from the expanded active site of GCYH-IB. The most potent of these compounds, G3, is selective for GCYH-IB, supporting the premise that potent and selective inhibitors of GCYH-IB could constitute a new class of small molecule antibiotics.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942202PMC
http://dx.doi.org/10.1016/j.bmcl.2019.126818DOI Listing

Publication Analysis

Top Keywords

gtp cyclohydrolase
8
active site
8
site gcyh-ib
8
gcyh-ib
5
structure-based design
4
design guanosine
4
guanosine analogue
4
analogue inhibitors
4
inhibitors targeting
4
targeting gtp
4

Similar Publications

Background: Variants in the gene, encoding guanosine triphosphate cyclohydrolase, are associated with dopa-responsive dystonia (DRD) and are considered risk factors for parkinson's disease.

Methods: Comprehensive neurological assessments documented motor and non-motor symptoms in a Chinese family affected by DRD. Whole-exome sequencing (WES) was employed to identify potential mutations, with key variants confirmed by Sanger sequencing and analyzed for familial co-segregation.

View Article and Find Full Text PDF

Cross-species RNAi therapy via AAV delivery alleviates neuropathic pain by targeting GCH1.

Neurotherapeutics

December 2024

Department of Neurosurgery, Yonsei University College of Medicine, Seoul, Republic of Korea; Department of Neurosurgery, Brain Research institute, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address:

Tetrahydrobiopterin (BH4) expression is normally strictly controlled; however, its intracellular levels increase considerably following nerve damage. GTP cyclohydrolase I (GCH1) plays a crucial role in regulating BH4 concentration, with an upregulation observed in the dorsal root ganglion in cases of neuropathic pain. In this study, we aimed to develop and evaluate the clinical potential of an RNA interference-based adeno-associated virus (AAV) targeting GCH1 across various species to decrease BH4 levels and, consequently, alleviate neuropathic pain symptoms.

View Article and Find Full Text PDF

Neuropathic pain is a chronic pain condition that is primarily caused by underlying neurological damage and dysfunction. Recent studies have identified microRNAs (miRNAs) as a key factor in the treatment of neuropathic pain. To explore the effects of miR-133a-3p on neuroinflammation and neuropathic pain via GTP cyclohydrolase (GCH1), and its underlying mechanisms.

View Article and Find Full Text PDF

Tetrahydrobiopterin as a rheostat of cell resistance to oxidant injury.

Redox Biol

February 2025

Department of Biophysics and Redox Biology Program, Medical College of Wisconsin, Milwaukee, WI, 53226, USA. Electronic address:

Tetrahydrobiopterin (BH4) deficiency is caused by genetic abnormalities that impair its biosynthesis and recycling, which trigger neurochemical, metabolic, and redox imbalances. Low BH4 levels are also associated with hypoxia, reperfusion reoxygenation, endothelial dysfunction, and other conditions that are not genetically determined. The exact cause of changes in BH4 in nongenetic disorders is not entirely understood, but a role for oxidant species has been implicated.

View Article and Find Full Text PDF

CTRP13 attenuates atherosclerosis by inhibiting endothelial cell ferroptosis via activating GCH1.

Int Immunopharmacol

December 2024

Harbin Medical University, Harbin 150001, PR China; Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University, Harbin 150001, PR China; Key Laboratory of Myocardial Ischemia, Ministry of Education, Harbin 150001, PR China. Electronic address:

C1q/TNF-related protein 13 (CTRP13) is a secreted adipokine that has been shown to play an important role in a variety of cardiovascular diseases. However, the effect of CTRP13 on ferroptosis of endothelial cells and its underlying mechanism remain unclear. In the present study, we analyzed the effects of CTRP13 on endothelial dysfunction in high-lipid-induced ApoE mice and ox-LDL-induced mouse aortic endothelial cells (MAECs).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!